InsidersTradesSigma
Follow the Contineum Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Contineum Therapeutics, Inc. has recorded 41 reports. Market capitalisation: €611m. The latest transaction was filed on 8 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Lorrain Daniel S.. Every trade is accessible without an account.
41
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€535,425
16 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Contineum Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$23.43.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 September 2026
Declarations41 total
2,500 shares@ US$16.700.0068% mcap15.4% of flowCommonSEC144:0001950047-26-009206
2,500 shares@ US$1.010.0004% mcap1.9% of flowClass A Common StockSEC:0001628280-26-060962:0
2,500 shares@ US$16.45660.0067% mcap30.3% of flowClass A Common StockSEC:0001628280-26-060962:1
2,500 shares@ US$15.490.0066% mcap17.0% of flowCommonSEC144:0001950047-26-007517
2,500 shares@ US$1.010.0004% mcap2.8% of flowClass A Common StockSEC:0001628280-26-052031:0
2,500 shares@ US$16.01160.0069% mcap43.8% of flowClass A Common StockSEC:0001628280-26-052031:1
1,015 shares@ US$1.010.0002% mcap0.2% of flowClass A Common StockSEC:0001628280-26-047909:0
1,015 shares@ US$16.000.0028% mcap3.3% of flowClass A Common StockSEC:0001628280-26-047909:1
25 shares@ US$1.010.0000% mcap0.0% of flowClass A Common StockSEC:0001628280-26-047909:2
25 shares@ US$16.000.0001% mcap0.1% of flowClass A Common StockSEC:0001628280-26-047909:3
2,500 shares@ US$14.560.0063% mcap100.0% of flowCommonSEC144:0001950047-26-006968
2,500 shares@ US$1.010.0005% mcap4.7% of flowClass A Common StockSEC:0001628280-26-047710:0
2,500 shares@ US$16.000.0074% mcap75.1% of flowClass A Common StockSEC:0001628280-26-047710:1
9,520 shares@ US$16.390.027% mcap26.6% of flowCommonSEC144:0001950047-26-006723
7,500 sharesClass A Common StockSEC:0001628280-26-046653:0
2,500 sharesClass A Common StockSEC:0001628280-26-046653:1
10,000 sharesClass A Common StockSEC:0001628280-26-046653:2
10,833 sharesClass A Common StockSEC:0001628280-26-046654:0
10,833 sharesClass A Common StockSEC:0001628280-26-046654:1
10,833 shares@ US$15.000.028% mcap100.0% of flowCommonSEC144:0001950047-26-006664
10,000 shares@ US$15.000.026% mcap80.5% of flowCommonSEC144:0001950047-26-006666
28,826 shares@ US$15.000.075% mcap73.4% of flowCommonSEC144:0001950047-26-006667
4,170 shares@ US$13.15640.011% mcap8.2% of flowClass A Common StockSEC:0001628280-26-039641:0
3,870 shares@ US$13.060.010% mcap10.3% of flowClass A Common StockSEC:0001628280-26-029435:0
4,170 shares@ US$13.43260.011% mcap11.6% of flowClass A Common StockSEC:0001628280-26-023949:0
25 of 41 declarations
关于 Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc.（股票代码：CTNM）是一家在美国纳斯达克上市的美国生物制药公司，应将其视为一家临床阶段的生物技术公司，而非商业阶段的药物制造商。该公司总部位于加利福尼亚州圣地亚哥，于2009年在特拉华州注册成立。2023年11月，公司名称从 Pipeline Therapeutics, Inc. 变更为 Contineum Therapeutics, Inc.，以反映其对神经科学、炎症和免疫学（NI&I）更广泛的关注。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1855175/000162828026030614/ctnm-20260331.htm?utm_source=openai)） Contineum 的核心业务是发现和开发新型口服小分子疗法，旨在解决存在重大未满足医疗需求的疾病。该公司的模式以内部研发和临床进展为中心，而非通过已上市产品产生收入。其主要资产是 PIPE-791，一种脑渗透性 LPA1 受体拮抗剂，正在开发用于特发性肺纤维化（IPF）。另一个关键项目是 PIPE-307，一种选择性毒蕈碱 M1 受体拮抗剂，正在神经系统适应症中推进。Contineum 还提名了 CTX-343，一种外周限制性 LPA1R 拮抗剂，这表明该公司正在围绕相关生物学构建一个多资产发现平台。（[contineum-tx.com](https://contineum-tx.com/pipeline/?utm_source=openai)） 从竞争角度来看，Contineum 在生物技术领域占据着一个专业的利基市场。其投资案例建立在科学差异化、靶点验证以及通过令人信服的安全性和有效性数据推动项目进入临床的能力之上。其产品组合涵盖两个有吸引力的治疗主题：通过 PIPE-791 治疗纤维化/呼吸系统疾病，以及通过 PIPE-307 治疗中枢神经系统疾病。一个显著的战略特点是与 Janssen 签订的 PIPE-307 全球许可和开发协议，这提供了外部验证，并可能拓宽了开发和未来价值创造的途径。（[ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/pipeline-therapeutics-announces-global-license-and-development/?utm_source=openai)） 公司近期亮点主要集中在临床执行和里程碑交付上。在整个2025年，Contineum 报告的财务和运营更新显示研发支出增加，这主要得益于 PIPE-791 和 PIPE-307 的进展，同时也预示着即将公布的临床试验顶线数据。因此，对于股票投资者而言，CTNM 应被视为一家高风险、高回报的临床生物技术公司，拥有明确的管线、重要的科学抱负，并高度依赖试验结果和合作执行。（[ir.contineum-tx.com](https://ir.contineum-tx.com/news-releases/news-release-details/contineum-therapeutics-reports-second-quarter-2025-financial/?utm_source=openai)）
